You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 8,129,114


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,129,114
Title:Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
Abstract: EGFR biomarkers useful in a method for predicting the likelihood that a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, wherein the method comprises (a) measuring in the mammal the level of at least one biomarker selected from epiregulin and amphiregulin, (b) exposing a biological sample from the mammal to the EGFR modulator, and (c) following the exposing of step (b), measuring in the biological sample the level of the at least one biomarker, wherein an increase in the level of the at least one biomarker measured in step (c) compared to the level of the at least one biomarker measured in step (a) indicates an increased likelihood that the mammal will respond therapeutically to the method of treating cancer.
Inventor(s): Ford; Shirin K. (Princeton, NJ), Clark; Edwin A. (Pennington, NJ), Huang; Xin (Princeton, NJ)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:11/990,713
Patent Claims:1. A method for predicting the likelihood a mammal that has a wild-type K-ras will respond therapeutically to a method of treating colorectal cancer with a therapy that comprises administering an anti-EGFR antibody that inhibits binding of EGF to EGFR, wherein the method for predicting comprises measuring the mRNA expression level of both epiregulin and amphiregulin biomarkers in a colorectal cancer sample of said mammal, wherein an increase in the level of said biomarkers relative to a predetermined level of said biomarkers in a colorectal cancer sample indicates an increased likelihood the mammal will respond therapeutically to said method of treating colorectal cancer.

2. The method of claim 1 further comprising the step of measuring at least one additional biomarker selected from Table 1.

3. The method of claim 1 wherein said colorectal cancer sample is a tissue sample comprising colorectal cancer cells and said tissue is fixed, paraffin-embedded, fresh, or frozen.

4. The method of claim 1 that further comprises the step of determining whether said colorectal cancer sample has the presence of a mutated K-RAS, wherein detection of a mutated K-RAS indicates a decreased likelihood the mammal will respond therapeutically to said method of treating colorectal cancer.

5. The method according to a claim 1, wherein said mammal is human.

6. The method according to claim 1, wherein said mammal is selected from the group consisting of: rat, mouse, dog, rabbit, pig sheep, cow, horse, cat, primate, and monkey.

7. The method according to claim 1, wherein said anti-EGFR antibody is selected from the group consisting of a monoclonal, polyclonal or single chain antibody.

8. The method of claim 7, wherein said anti-EGFR antibody cetuximab.

9. The method according to claim 8, further comprising the step of administering said anti-EGFR antibody to said mammal if the level of said biomarkers is increased relative to a predetermined level of said biomarkers in a colorectal cancer sample, wherein said anti-EGFR antibody inhibits binding of EGF to EGFR.

10. The method according to claim 7, wherein said anti-EGFR antibody is panitumumab.

11. The method according to claim 10, further comprising the step of administering said anti-EGFR antibody to said mammal if the level of said biomarkers is increased relative to a predetermined level of said biomarkers in a colorectal cancer sample, wherein said anti-EGFR antibody inhibits binding of EGF to EGFR.

12. The method according to claim 1, further comprising the step of administering said anti-EGFR antibody to said mammal if the level of said biomarkers is increased relative to a predetermined level of said biomarkers in a colorectal cancer sample, wherein said anti-EGFR antibody inhibits binding of EGF to EGFR.

13. A method for predicting the likelihood a mammal that has a wild-type K-ras will respond therapeutically to a method of treating colorectal cancer comprising administering an anti-EGFR antibody that inhibits binding of EGF to EGFR, wherein the method comprises: (a) measuring the mRNA expression level of both epiregulin and amphiregulin biomarkers in a colorectal cancer sample of said mammal; (b) administering an anti-EGFR antibody to said mammal, wherein said anti-EGFR antibody inhibits binding of EGF to EGFR; (c) following the administering step (b), measuring in a biological sample of said mammal the mRNA expression level of said biomarkers, wherein an increase in the level said biomarkers measured in step (c) compared to the level of said biomarkers measured in step (a) indicates an increased likelihood the mammal will respond therapeutically to said method of treating colorectal cancer.

14. The method according to claim 13, wherein said anti-EGFR antibody is selected from the group consisting of: a monoclonal, polyclonal or single chain antibody.

Details for Patent 8,129,114

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Eli Lilly And Company ERBITUX cetuximab Injection 125084 02/12/2004 ⤷  Try a Trial 2025-08-24
Eli Lilly And Company ERBITUX cetuximab Injection 125084 03/28/2007 ⤷  Try a Trial 2025-08-24
Amgen, Inc. VECTIBIX panitumumab Injection 125147 09/27/2006 ⤷  Try a Trial 2025-08-24
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.